论文部分内容阅读
在进行了一年的可行性研究后,今年初,辉瑞在中国开始了一项试点项目。在完成的试点项目基础上,我们设立了研发中心,扩大在新药生物统计领域的研发规模并拓展到全球研发的其他领域。辉瑞是首家将先进的药品开发支持技术能力引入中国的跨国医药企业。这个研发中心将通过提供研究方案设计,对全球医药研发临床试验进行数据统计、分析和管理,为法规和安全报告提供信息支持。同时,它也将成为辉瑞公司在亚洲地区药品临床试验管理规范的培训中心。
After a year of feasibility studies, Pfizer started a pilot project in China earlier this year. Based on the completed pilot project, we have set up a research and development center to expand the R & D scale in the field of new drug biostatistics and expand to other areas of global R & D. Pfizer is the first multinational pharmaceutical company to introduce advanced drug development and support technology capabilities into China. The R & D center will provide data support for statutory and safety reporting by providing research protocol design, data statistics, analysis and management of clinical trials of pharmaceutical research and development worldwide. At the same time, it will also become Pfizer’s training center for the management of pharmaceutical clinical trials in Asia.